Biotech Spotlight: Alphamab Oncology, China
Founded in 2009 by CEO Dr XU Ting, Alphamab started its journey as a protein engineering company with the ultimate dream of becoming, as many Chinese biotechs aspire, a global…
Address: 151 Malianwa North Road, Haidian District, the hospital 100 094
Tel: 010 -62896868
Web: http://www.newlife.org.cn/
Beijing Pharma and Biotech Center (BPBC) is a Beijing municipal governmental agency, dedicated to stimulating innovation, and promoting industrial development for the pharmaceutical and biotech industry, by providing services diverse as consultation on policies, industry, and strategies, project management, international liaison, partnership seeking, and events organization. BPBC has large network of scientists from top institutes and universities, executives from biotech and pharmaceutical companies, local science parks and government.
Beijing Pharma and Biotech Center’s basis is to promote collaborations between these groups.
Industry coordination
Founded in 2009 by CEO Dr XU Ting, Alphamab started its journey as a protein engineering company with the ultimate dream of becoming, as many Chinese biotechs aspire, a global…
Since the Chinese government unrolled an unprecedented volume-based procurement initiative for essential drugs used in the public hospital system in November 2018 in a bid to curb unsustainable healthcare expenditures,…
A roundup of the latest news from Chinese pharma, including Big Pharma players losing out in the latest round of domestic procurement bidding, updates on Sinopharm’s experimental COVID-19 vaccine, biotech…
The only company in our Summer 2020 edition of InFocus: 5 Biotechs to Watch in China to be helmed by a non-founding CEO, I-Mab Biopharma has advanced since its establishment…
Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain…
Probably one of the most recognisable Chinese biotechs globally, Zai Lab may only be seven years old but the company has progressed rapidly in becoming a NASDAQ-listed company with not…
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies…
A roundup of latest news from Chinese pharma and biotech, including a record high share price for Hansoh, strategic healthcare partnerships, venture capital gains, and recent IPO news from Sunshine…
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
With its brand new hub in Shanghai dedicated to research, business development and venture funding, German pharma giant Boehringer Ingelheim is taking a step further toward accessing innovation from the…
Dr Qing Liu, Arctic Vision’s VP for Clinical & Regulatory Affairs, shares her key priorities and the potential for top-line ophthalmological innovations in the Chinese market. Unmet medical needs…
See our Cookie Privacy Policy Here
